U.S. markets close in 4 hours 32 minutes

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.71+0.37 (+1.66%)
As of 11:27AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close22.34
Bid22.87 x 900
Ask22.87 x 1000
Day's Range22.55 - 22.93
52 Week Range18.05 - 31.78
Avg. Volume1,026,911
Market Cap3.032B
Beta (5Y Monthly)0.26
PE Ratio (TTM)6.29
EPS (TTM)3.61
Earnings DateMay 03, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
62% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VIR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vir Biotechnology, Inc.
    VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Simply Wall St.

    Strong week for Vir Biotechnology (NASDAQ:VIR) shareholders doesn't alleviate pain of three-year loss

    For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...

  • GlobeNewswire

    Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

    SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at and will be archived the


    As Covid Threat Weakens, This Biotech Is Still Worth a Shot

    Vir Biotechnology, Inc. is a biotech company facing the apparent winding down of the Covid crisis while sitting on a huge amount of net cash -- and with other projects in the pipeline. Vir uses this information to develop way of treating infectious diseases. This small biotech has one approved Covid-19 therapy in collaboration with GlaxoSmithKline (with significantly declining revenue) called sotrovimab and four others in the clinic.